Edelman R, Scheidt K B
J Infect Dis. 1977 Dec;136 Suppl:S500-6. doi: 10.1093/infdis/136.supplement_3.s500.
One hundred thirty-three healthy, at-risk Fort Detrick laboratory workers were inoculated with 400 chick cell-agglutinating (CCA) units of influenza A/New Jersey/76 split-virus vaccine (Wyeth Laboratories, Philadelphia, Pa.). Systemic and local reactions were infrequent, mild, and comparable to those of a sham-vaccinated group of volunteers. Only 28% of subjects 19-24 years old developed titers of hemagglutination-inhibiting (HAI) antibody of greater than or equal to 1:20, whereas titers of 91%-100% of subjects 25-62 years old reached this level. Thirty-one vaccinated subjects with no or low titers of antibody were given a booster dose (400 CCA units) of Wyeth vaccine six weeks after the first inoculation. Only 58%-67% of these vaccinees achieved HAI titers of greater than or equal to 1:20 after the booster. Fourteen persons required a second booster dose for protection; after vaccination with 400 CCA units of whole-virus vaccine from Merck Sharp and Dohme (West Point, Pa.), 89%-100% of the 14 vaccinees finally achieved HAI titers of greater than or equal to 1:20. The split-virus vaccine was safe, but it was poorly antigenic as a primary vaccine in persons 19-24 years old and as a booster in persons of all ages who have poor antibody responses in general.
133名健康且处于风险中的迪特里克堡实验室工作人员接种了400鸡胚细胞凝集(CCA)单位的甲型流感/新泽西/76裂解病毒疫苗(惠氏实验室,宾夕法尼亚州费城)。全身和局部反应很少见,且症状轻微,与接受假疫苗接种的志愿者组的反应相当。19至24岁的受试者中只有28%产生了血凝抑制(HAI)抗体效价大于或等于1:20,而25至62岁的受试者中有91% - 100%达到了这一水平。31名抗体效价为零或较低的接种受试者在首次接种六周后接受了惠氏疫苗的加强剂量(400 CCA单位)。这些接种者中只有58% - 67%在加强接种后达到了HAI效价大于或等于1:20。14人需要第二次加强剂量以获得保护;在用默克公司(宾夕法尼亚州西点)的400 CCA单位全病毒疫苗接种后,这14名接种者中有89% - 100%最终达到了HAI效价大于或等于1:20。这种裂解病毒疫苗是安全的,但作为主要疫苗,它在19至24岁人群中抗原性较差,在所有年龄段中抗体反应普遍较差的人群中作为加强疫苗时抗原性也较差。